Dydrogesterone in threatened abortion: Pregnancy outcome

Omar, Mohd Hashim; Mashita, M. K.; Lim, Pei Shan; Jamil, Maslina

doi:10.1016/j.jsbmb.2005.08.013

Cited by 68 publications

(48 citation statements)

References 21 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(3,5,40) This percentage, however, is lower than that of the 1992 study conducted in Singapore, which reported that 55.3% of women who experienced a threatened miscarriage in the first trimester progressed to a complete miscarriage at any time during their pregnancy. (22) The shorter follow up duration in our study, and possibly improvements in the management of threatened miscarriage over the years, may account for this discrepancy.…”

Section: Discussionmentioning

confidence: 66%

A prospective study of risk factors for first trimester miscarriage in Asian women with threatened miscarriage

Kouk¹,

Neo²,

Malhotra³

et al. 2013

smedj

View full text Add to dashboard Cite

RESUlTSOf the 139 women included for data analysis, 36 (25.9%) had a miscarriage, mostly within two weeks of presentation. The results of our study showed that women aged ≥ 34 years were more likely to miscarry (hazard ratio [HR] = 1.95). Compared to women whose partner was 20-30 years of age, women whose partner was ≥ 41 years of age also had a higher likelihood of experiencing a miscarriage (HR = 8.33). However, the presence of nausea (HR = 0.33) and a high stress score (i.e. ≥ 17) on the Perceived Stress Scale (HR = 0.49) were associated with a reduced likelihood of miscarriage. CONClUSIONOlder pregnant women experiencing a threatened miscarriage should be counselled about their higher risk of miscarriage, especially if they have an older partner.

show abstract

Section: Discussionmentioning

confidence: 66%

A prospective study of risk factors for first trimester miscarriage in Asian women with threatened miscarriage

Kouk¹,

Neo²,

Malhotra³

et al. 2013

smedj

View full text Add to dashboard Cite

show abstract

“…The difference in the rate of abortion may be due to the time period of treatment between the studies. Studies from Poland and Malaysia have reported that dydrogesterone supplementation has protective effects on threatened abortion (11,12). A systematic review (13) also reported a 13% (44 of 335) miscarriage rate after dydrogesterone administration compared with 24% in control women (odds ratio for miscarriage 0.47, 95% CI ¼ 0.31-0.7, and an 11% absolute reduction in the miscarriage rate).…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial

Kumar

Begum

Prasad

et al. 2014

Fertility and Sterility

View full text Add to dashboard Cite

“…Although a meta-analysis by Haas and Ramsey [133] did not confirm any positive role for progesterone in sporadic miscarriage, a further subgroup analysis of women with RSM in that study showed that progesterone therapy was positively associated with a significant reduction in the miscarriage rate in those with RSM compared with placebo or no treatment. Duphaston (dydrogesterone, a synthetic progesterone), administered as tablets, was not only significantly associated with a prolongation of pregnancy in patients with threatened miscarriage but was also significantly associated with successful viable pregnancies and a reduction in miscarriages in patients with RSM who were treated with duphaston [134,135]. Duphaston therapy has been associated with a shift of Th1 to Th2 cytokines, and thus, contributes to the promotion/progression of pregnancies.…”

Section: Treatment Of Rsmmentioning

confidence: 99%

Recurrent Spontaneous Miscarriage Is Still a Challenging Diagnostic and Therapeutic Quagmire

Diejomaoh¹

2014

Med Princ Pract

View full text Add to dashboard Cite

Recurrent spontaneous miscarriage (RSM), affecting 1-2% of women of reproductive age seeking pregnancy, has been a clinical quagmire and a formidable challenge for the treating physician. There are many areas of controversy in the definition, aetiology, investigations and treatment of RSM. This review will address the many factors involved in the aetiology of RSM which is multifactorial in many patients, with antiphospholipid syndrome (APS) being the most recognized aetiological factor. There is no identifiable cause in about 40-60% of these patients, in which case the condition is classified as idiopathic or unexplained RSM. The RSM investigations are extensive and should be undertaken in dedicated, specialized, well-equipped clinics/centres where services are provided by trained specialists. The challenges faced by the treating physician are even more overwhelming regarding the decision of what should be the most appropriate therapy offered to patients with RSM. Our review will cover the diverse modalities of therapy available including the role of preimplantation genetic testing using recent microarray technology, such as single nucleotide polymorphism and comparative genomic hybridization, as well as preimplantation genetic diagnosis; the greatest emphasis will be on the treatment of APS, and there will be important comments on the management of patients presenting with idiopathic RSM. The controversial areas of the role of natural killer cells in RSM, the varied modalities in the management of idiopathic RSM and the need for better-planned studies will be covered as well.

show abstract

Dydrogesterone in threatened abortion: Pregnancy outcome

Cited by 68 publications

References 21 publications

A prospective study of risk factors for first trimester miscarriage in Asian women with threatened miscarriage

A prospective study of risk factors for first trimester miscarriage in Asian women with threatened miscarriage

RETRACTED: Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial

Recurrent Spontaneous Miscarriage Is Still a Challenging Diagnostic and Therapeutic Quagmire

Contact Info

Product

Resources

About